VP Clinical Development & Regulatory AffairsABK Biomedical Inc., Canada
Disclosure information not submitted.
Multimodal Imageable Eye90 microspheres® Radioembolization for Hepatocellular Carcinoma - 6 Month Interim Safety and Efficacy and 3 Month Liver Volume Results from a First in Human Trial
Monday, March 25, 20243:45 PM – 3:54 PM MT
Route90 US IDE Pivotal Study Early Results in Radioembolization of Hepatocellular Carcinoma (HCC) with Imageable Y90 Microspheres
Monday, March 25, 20243:00 PM – 3:09 PM MT